Hologic, Inc. (NASDAQ:HOLX) Shares Sold by New South Capital Management Inc.

New South Capital Management Inc. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,288 shares of the medical equipment provider’s stock after selling 7,151 shares during the period. New South Capital Management Inc. owned about 0.08% of Hologic worth $13,357,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. General Partner Inc. purchased a new stake in Hologic during the fourth quarter worth about $26,000. Venturi Wealth Management LLC increased its stake in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the period. Finally, Smithfield Trust Co increased its stake in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HOLX. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday. Evercore ISI cut their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Price Performance

HOLX stock opened at $62.08 on Thursday. The company has a market capitalization of $13.93 billion, a P/E ratio of 19.58, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $61.70 and a twelve month high of $84.67. The business has a 50 day simple moving average of $68.77 and a 200-day simple moving average of $75.64. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.